文献速递浆细胞疾病造血干细胞移植与细胞治疗

多发性骨髓瘤患者自体干细胞移植后PET阳性时强化治疗

Intensifying treatment in PET-positive multiple myeloma patients after upfront autologous stem cell transplantation.
PubMed 文献 · Leukemia · 2023-08-11

该II期研究筛查一线自体干细胞移植(ASCT)后达非常好的部分缓解(VGPR)或更好的多发性骨髓瘤患者,PET阳性者接受4个28天周期卡非佐米-来那度胺-地塞米松(KRd)治疗。159例筛查患者中53例(33%)PET阳性,其中57%为MRD阴性,KRd巩固使33%的PET阳性患者转为PET阴性。

要点

  • ASCT后PET阳性在多发性骨髓瘤中与无进展生存和总生存降低强相关。
  • PET阳性患者中57%为MRD阴性,提示PET与MRD评估互补。
  • KRd巩固治疗使33%的PET阳性患者转为PET阴性。

核心结论

  • ASCT后PET在相当比例达VGPR或更好的患者中检测到残留病,即使MRD阴性亦如此,KRd巩固治疗改变了33%患者的PET状态。

研究设计与样本

  • II期研究,筛查一线ASCT后达VGPR或更好的多发性骨髓瘤患者,PET阳性者接受4个28天周期KRd治疗,治疗前后行流式细胞术MRD分析。

主要发现

  • 共159例患者接受PET筛查,53例(33%)为PET阳性。
  • PET阳性患者中57%为MRD阴性,表明PET与MRD评估互补。
  • KRd巩固使33%的PET阳性患者转为PET阴性,MRD阴性患者较MRD阳性患者更可能转阴。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

18F-Fluorodeoxyglucose positron emission tomography/computed tomography (PET) positivity after first-line treatment with autologous stem cell transplantation (ASCT) in multiple myeloma is strongly correlated with reduced progression-free and overall survival. However, PET-positive patients who achieve PET negativity after treatment seem to have comparable outcomes to patients who were PET negative at diagnosis. Hence, giving PET-positive patients additional treatment may improve their outcome. In this phase II study, we screened first-line patients with very good partial response (VGPR) or better after ASCT with PET. PET-positive patients received four 28-day cycles of carfilzomib-lenalidomide-dexamethasone (KRd). Flow cytometry-based minimal residual disease (MRD) analysis was performed before and after treatment for correlation with PET. Overall, 159 patients were screened with PET. A total of 53 patients (33%) were PET positive and 57% of PET-positive patients were MRD negative, demonstrating that these response assessments are complementary. KRd consolidation converted 33% of PET-positive patients into PET negativity. MRD-negative patients were more likely to convert than MRD-positive patients. In summary, PET after ASCT detected residual disease in a substantial proportion of patients in VGPR or better, even in patients who were MRD negative, and KRd consolidation treatment changed PET status in 33% of patients.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Nørgaard JN, Abildgaard N, Lysén A, et al. Intensifying treatment in PET-positive multiple myeloma patients after upfront autologous stem cell transplantation. Leukemia. 2023. PMID: 37568010. doi:10.1038/s41375-023-01998-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。